Viread tenofovir disoproxil fumarate: Additional Phase III data

Additional data from the double-blind Phase III Study 102 in 375 patients showed that at 72 weeks, 91% of those originally randomized to receive Viread had a virologic response (HBV DNA levels <400 co...